Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.

Dupilumab significantly improves the day-to-day symptom burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

The following is a summary of “Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR),” published in the October 2024 issue of Allergy and Immunology by Seys et al. Pivotal ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

The following is a summary of “Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP,” published in the August 2024 issue of Allergy and Immunology by Bachert et al.

More than 1,000,000 patients are being treated with Dupixent globally.1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one ...

A new study published in the Chest Journal showed that Dupilumab helps individuals with type 2 inflammation and chronic ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...